TECH - Philips' Gets FDA Recall for Trilogy Ventilator Glitch | Benzinga
Koninklijke Philips (NYSE: PHG) notified its customers about a possible power malfunction in its Trilogy Evo continuous ventilators and initiated a software update to resolve the same in March. The FDA classified this action as Class I level recall, the most serious type of recall, as the use of these devices without the software update may cause serious injuries or death. This recall is a correction and not a product removal. It includes all susceptible devices — Trilogy EVO, Trilogy EV300, Trilogy Evo O2, and Trilogy Evo Universal.
The company also informed that these ventilators can issue a "Battery Depleted" or "Loss of Power" alarm while sufficient power is still available due to the software issue.
Price Performance
For the past six months, PHG's shares have gained 29.5% compared with the industry's rise of 13.3%. The S&P 500 increased 16.2% in the same time frame.
Image Source: Zacks Investment Research
More on the Trilogy Ventilators
The Trilogy ventilators use a microprocessor-controlled blower to provide pressure support, pressure control, or volume control during breathing support. These devices are designed to aid those who need help breathing, and they can ...